Book a Meeting


Cancer Cells Surface Engineering Service

Cell surface engineering to provide new characteristics and functions to cells has drawn continuous interest from researchers in biomedical science. Many endeavors have been made to develop surface engineering techniques such as non-genetic cell membrane engineering that can circumvent genetic modification limitations. Based on leading-edge facilities and profound knowledge, the seasoned scientific team in Creative Biolabs has developed an integrated CellFace™ conjugate technology platform to bring our customers impeccable cancer cell surface engineering.

Cancer Cells Surface Engineering Service

Cancer cells mostly derive from genetic changes, and the surface engineering of cancer cells has been leveraged for both therapeutic and diagnostic purposes. For example, cell surface engineering of cancer cells with various immune modifiers and costimulatory agents can enhance the immune recognition and responsiveness of the cancer cell vaccines.

Creative Biolabs has years of experience in cell surface conjugation, providing high-quality cell surface engineering services for our global customers. We could use a variety of different technologies, such as cell-covalent conjugation and cell-noncovalent physical bioconjugation to meet each rigorous requirement and offer high-quality cancer cell-based conjugate to our customers. We will help you achieve your project goals quickly and cost-effectively through efficient management and proactive communication. Various types of cancer cell-based conjugates could be provided at Creative Biolabs, including but not limited to:

Applications of Cancer Cells Surface Engineering

Cancer cell surface engineering. Fig.1 Cancer cell surface engineering. (Wang, 2017)

Creative Biolabs is a leading service company with a world-class CellFace™ conjugate technology platform, supporting our customers for various cancer cell surface engineering programs. If you are interested in our services, please feel free to inquire us for more information.


  1. Shirota, H.; Klinman, D.M. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunology, Immunotherapy. 2011, 60(5), pp.659-669.
  2. Wang, H.; et al. Selective in vivo metabolic cell-labeling-mediated cancer targeting. Nature chemical biology. 2017, 13(4), pp.415-424.

All services are only provided for research purposes and Not for clinical use.

  • *
  • *
  • *

United Kingdom